NASDAQ:HUGE

FSD Pharma (HUGE) Stock Forecast, Price & News

$1.21

+0.02 (+1.68%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.19
▼
$1.22
50-Day Range: $1.07
▼
$1.60
52-Week Range: $0.62
▼
$2.10

Volume: 69,424 shs
Average Volume: 293,023 shs
Market Capitalization: $47.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About FSD Pharma (NASDAQ:HUGE) Stock

FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

HUGE Price History

30 days | 90 days | 365 days | Advanced Chart

HUGE Stock News Headlines

September 22, 2023 | finance.yahoo.com

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

September 13, 2023 | finance.yahoo.com

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

October 1, 2023 | Stansberry Research (Ad)

Experts: NVIDIA Now "Too Big to Succeed"

Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.

August 25, 2023 | finance.yahoo.com

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)

August 2, 2023 | msn.com

FSD Pharma signs licensing deal for alcohol detox drink Unbuzzd

July 10, 2023 | msn.com

FSD Pharma hires legal team to investigate suspected illegal trading

July 10, 2023 | finance.yahoo.com

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock

July 4, 2023 | finance.yahoo.com

FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors

October 1, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

June 30, 2023 | finance.yahoo.com

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

June 21, 2023 | bizjournals.com

Former FSD Pharma CEO Raza Bokhari back in court seeking $30.2M from former employer

June 21, 2023 | finance.yahoo.com

DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION

May 16, 2023 | bizjournals.com

Former pharma CEO ordered to pay former employer $2M for arbitration costs

May 16, 2023 | finance.yahoo.com

InvestmentPitch Media Video Discusses FSD Pharma’s Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement

May 12, 2023 | finance.yahoo.com

FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution

May 8, 2023 | finance.yahoo.com

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11

May 5, 2023 | markets.businessinsider.com

Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation

April 17, 2023 | finance.yahoo.com

GBB Drink Lab Sends a Cease-and-Desist Demand

April 17, 2023 | msn.com

Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis

April 17, 2023 | finance.yahoo.com

FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

April 12, 2023 | msn.com

FSD Pharma To Spin Out New Publicly Trading Subsidiary As Distribution To Shareholders

March 31, 2023 | finance.yahoo.com

FSD Pharma Announces Filing of Year-End 2022 Results

March 30, 2023 | finance.yahoo.com

FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors

March 22, 2023 | marketwatch.com

FSD Pharma Gets Green Light for Depression-Drug Clinical Trial in Australia

March 22, 2023 | finance.yahoo.com

FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

March 14, 2023 | msn.com

Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock

March 14, 2023 | finance.yahoo.com

FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock

See More Headlines

Receive HUGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter.

HUGE Company Calendar

Last Earnings: 7/20/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HUGE
CUSIP: N/A
CIK: 1771885
Web: fsdpharma.com
Phone: (416) 854-8884
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -111.46%
Return on Assets: -86.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.56
Quick Ratio: 1.56

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 39,040,000
Free Float: 35,711,000
Market Cap: $47.26 million
Optionable: Optionable
Beta: 0.61

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Zeeshan Saeed (Age 53)
Founder, CEO, Pres & Exec. Co-Chairman
Comp: $375.98k

Mr. Anthony John Durkacz (Age 47)
Founder & Exec. Co-Chairman
Comp: $375.98k

Mr. Nathan Coyle CPA (Age 42)
Chief Financial Officer
Comp: $191.89k

Mr. Donal Carroll CPA (Age 46)
Chief Operating Officer
Comp: $375.98k

Dr. Lakshmi P. Kotra BPHARM (Age 52)
Ph.D., CEO of Lucid & Director
Comp: $331.51k

Dr. Andrzej Chruscinski M.D.
Ph.D., VP of Clinical & Scientific Affairs of Lucid

Mr. Kevin Cassidy
VP of Quality-Lucid

Ms. Maryann Adesso
Corp. Sec.

Randell Mack
Pres of FSD BioSciences

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HUGE Stock - Frequently Asked Questions

How have HUGE shares performed in 2023?: FSD Pharma's stock was trading at $0.7884 at the start of the year. Since then, HUGE shares have increased by 53.6% and is now trading at $1.2106.
View the best growth stocks for 2023 here.
When is FSD Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 10th 2023.
View our HUGE earnings forecast.
How were FSD Pharma's earnings last quarter?: FSD Pharma Inc. (NASDAQ:HUGE) issued its earnings results on Thursday, July, 20th. The company reported ($0.14) EPS for the quarter.
What other stocks do shareholders of FSD Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB).

What is FSD Pharma's stock symbol?: FSD Pharma trades on the NASDAQ under the ticker symbol "HUGE."
How do I buy shares of FSD Pharma?: Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is FSD Pharma's stock price today?: One share of HUGE stock can currently be purchased for approximately $1.21.
How much money does FSD Pharma make?: FSD Pharma (NASDAQ:HUGE) has a market capitalization of $47.26 million. The company earns $-23,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.
How can I contact FSD Pharma?: FSD Pharma's mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The official website for the company is fsdpharma.com. The company can be reached via phone at (416) 854-8884 or via email at ir@fsdpharma.com.

This page (NASDAQ:HUGE) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial